Levonorgestrel-Releasing Intrauterine System versus Medical Therapy for Menorrhagia: A Systematic Review and Meta-Analysis

Abstract

Background:The aim of this study was to compare the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) with conventional medical treatment in reducing heavy menstrual bleeding. Material/Methods:Relevant studies were identified by a search of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and clinical trials registries (from inception to April 2014). Randomized controlled trials comparing the LNG-IUS with conventional medical treatment (mefenamic acid, tranexamic acid, norethindrone, medroxyprogesterone acetate injection, or combined oral contraceptive pills) in patients with menorrhagia were included. Results:Eight randomized controlled trials that included 1170 women (LNG-IUS, n=562; conventional medical treatment, n=608) met inclusion criteria. The LNG-IUS was superior to conventional medical treatment in reducing menstrual blood loss (as measured by the alkaline hematin method or estimated by pictorial bleeding assessment chart scores). More women were satisfied with the LNG-IUS than with the use of conventional medical treatment (odds ratio [OR] 5.19, 95% confidence interval [CI] 2.73-9.86). Compared with conventional medical treatment, the LNG-IUS was associated with a lower rate of discontinuation (14.6% vs. 28.9%, OR 0.39, 95% CI 0.20-0.74) and fewer treatment failures (9.2% vs. 31.0%, OR 0.18, 95% CI 0.10-0.34). Furthermore, quality of life assessment favored LNG-IUS over conventional medical treatment, although use of various measurements limited our ability to pool the data for more powerful evidence. Serious adverse events were statistically comparable between treatments. Conclusions:The LNG-IUS was the more effective first choice for management of menorrhagia compared with conventional medical treatment. Long-term, randomized trials are required to further investigate patient-based outcomes and evaluate the cost-effectiveness of the LNG-IUS and other medical treatments. MeSH Keywords: Menorrhagia • Meta-Analysis • Quality of LifeFull-text PDF:

Expanding Access to a New, More Affordable Levonorgestrel Intrauterine System in Kenya: Service Delivery Costs Compared With Other Contraceptive Methods and Perspectives of Key Opinion Leaders

“…Additional cost–benefit analyses of the LNG IUS conducted in Kenya and other developing countries are needed to compare the use of the product with other therapeutic interventions, including for treatment of heavy menstrual bleeding. 28 - 30 …”

New developments in intrauterine device use: focus on the US

“…It is generally recognized that the LNG-IUS-20 is the most effective medical therapy for heavy menstrual bleeding. 91 , 92 In the original clinical trial in the US, therapeutic success was defined as decreasing blood loss by at least 50% and normalizing loss at or below 80 mL/cycle; 85% of LNG-IUS users achieved both of those objectives. 93 Since that study, extensive work has been performed comparing LNG-IUS effectiveness to a wide range of other treatments for heavy menstrual bleeding due to uterine pathology, systemic diseases, exogenous medications, and idiopathic diseases.…”

Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis

“…Finally, we excluded papers on women with heavy menstrual bleeding because of structural (ie, uterine fibroid tumors) or hormonal disease because the LNG-IUS differentially impacts menstruation depending on baseline blood loss volume 15 . Further, numerous systematic reviews on treating heavy menstrual blood loss with the LNG-IUS have been published already 16, 17, 18…”